15-year cause specific and all-cause survival following brachytherapy for prostate cancer: Negative impact of long-term hormonal therapy

Journal of Urology

Volumn 192, Issue 3, 2014, Pages 754-759

  Stone, Nelson N ^a   Stock, Richard G ^a  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

Author keywords

antiandrogens; brachytherapy; mortality; prostatic neoplasms; radiotherapy

Indexed keywords

ANTIANDROGEN; IODINE 125; PALLADIUM 103;

ADULT; AGED; ARTICLE; BRACHYTHERAPY; CANCER MORTALITY; CANCER SURVIVAL; CAUSE SPECIFIC SURVIVAL; DIABETES MELLITUS; EMPHYSEMA; EXTERNAL BEAM RADIOTHERAPY; HEART ATRIUM FIBRILLATION; HIGH RISK POPULATION; HORMONAL THERAPY; HUMAN; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROSTATE CANCER; SMOKING; SURVIVAL RATE; VERY ELDERLY;

ANTIANDROGENS; BRACHYTHERAPY; MORTALITY; PROSTATIC NEOPLASMS; RADIOTHERAPY;

ADULT; AGED; AGED, 80 AND OVER; ANDROGEN ANTAGONISTS; BRACHYTHERAPY; COMBINED MODALITY THERAPY; HUMANS; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; PROSTATIC NEOPLASMS; SURVIVAL RATE; TIME FACTORS;

EID: 84906077312     PISSN: 00225347     EISSN: 15273792     Source Type: Journal    
DOI: 10.1016/j.juro.2014.03.094     Document Type: Article

References (29)

1. M.V. Pilepich, K. Winter, and M.J. John et al. Phase III radiation therapy oncology group (RTOG) trial 86-10 of androgen deprivation adjuvant to definitive radiotherapy in locally advanced carcinoma of the prostate Int J Radiat Oncol Biol Phys 50 2001 1243
2. M. Bolla, L. Collette, and L. Blank et al. Long-term results with immediate androgen suppression and external irradiation in patients with locally advanced prostate cancer (an EORTC study): a phase III randomised trial Lancet 360 2002 103
3. A.V. D'Amico, J. Manola, and M. Loffredo et al. 6-Month androgen suppression plus radiotherapy versus radiotherapy alone for patients with clinically localized prostate cancer JAMA 292 2004 821
4. M.G. Oefelein Androgen suppression therapy and prostate cancer: balancing the harms and the benefits Cancer 113 2008 3275
5. N.N. Stone, and R.G. Stock The effect of brachytherapy, external beam irradiation and hormonal therapy on prostate volume J Urol 177 2007 925
6. N.N. Stone, L. Potters, and B.J. Davis et al. Multicenter analysis of effect of high biologic effective dose on biochemical failure and survival outcomes in patients with Gleason score 7-10 prostate cancer treated with permanent prostate brachytherapy Int J Radiat Oncol Biol Phys 73 2009 341
7. R.G. Stock, N.N. Stone, and M.F. Wesson et al. A modified technique allowing interactive ultrasound guided three-dimensional transperineal prostate implantation Int J Radiat Oncol Biol Phys 32 1995 219
8. N.N. Stone, S. Hong, and Y.C. Lo et al. Comparison of intraoperative dosimetric implant representation to post-implant dosimetry in patients receiving prostate brachytherapy Brachytherapy 2 2003 17
9. R.G. Stock, N.N. Stone, and J. Cesaretti et al. Biologically effective dose values for prostate brachytherapy: effects on PSA failure and posttreatment biopsies Int J Radiat Oncol Biol Phys 64 2006 527
10. J.E. Sylvester, P.D. Grimm, and J. Wong et al. Fifteen-year biochemical relapse-free survival, cause-specific survival and overall survival following I125 prostate brachytherapy in clinically localized prostate cancer Int J Radiat Oncol Biol Phys 81 2011 376
11. M. Han, A.W. Partin, and C.R. Pound et al. Long-term biochemical disease-free and cancer-specific survival following anatomic radical retropubic prostatectomy. The 15-year Johns Hopkins experience Urol Clin North Am 28 2001 555
12. J.K. Mullins, Z. Feng, and B.J. Trock et al. The impact of anatomical radical retropubic prostatectomy on cancer control: the 30-year anniversary J Urol 188 2012 2219
13. S. Shikanov, M. Kocherginsky, and A.L. Shalhav et al. Cause-specific mortality following radical prostatectomy Prostate Cancer Prostatic Dis 15 2012 106
14. R.M. Hoffman, K. Koyama, and K.H. Fan et al. Mortality after radical prostatectomy or external beam radiotherapy for localized prostate cancer J Natl Cancer Inst 105 2013 711
15. K.G. Nepple, A.J. Stephenson, and D. Kallogjeri et al. Mortality after prostate cancer treatment with radical prostatectomy, external-beam radiation therapy, or brachytherapy in men without comorbidity Eur Urol 64 2013 372
16. R. Jacob, A.L. Hanlon, and E.M. Horwitz et al. The relationship of increasing radiotherapy dose to reduced distant metastases and mortality in men with prostate cancer Cancer 100 2004 538
17. X. Shen, S.W. Keith, and M.V. Mishra et al. The impact of brachytherapy on prostate cancer specific mortality for definitive radiation therapy of high-grade prostate cancer: a population-based analysis Int J Radiat Oncol Biol Phys 83 2012 1154
18. J.E. Johansson, O. Andre, and S.O. Andersson et al. Natural history of early, localized prostate cancer JAMA 291 2004 2713
19. P.C. Albertsen, J.A. Hanley, and J. Fine 20-Year outcomes following conservative management of clinically localized prostate cancer JAMA 293 2005 2095
20. C.D. Bahler, R.S. Foster, and R. Bihrle et al. Radical prostatectomy as initial monotherapy for patients with pathologically confirmed high-grade prostate cancer BJU Int 105 2009 1372
21. M.E. Charlson, P. Pompei, and K.L. Ales et al. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation J Chronic Dis 40 1987 373
22. T.J. Daskivich, K.H. Fan, and T. Koyama et al. Effect of age, tumor risk, and comorbidity on competing risks for survival in a U.S. population-based cohort of men with prostate cancer Ann Intern Med 158 2013 709
23. H.K. Tsai, A.V. D'Amico, and N. Sadetsky et al. Androgen deprivation therapy for localized prostate cancer and the risk of cardiovascular mortality J Natl Cancer Inst 99 2007 1516
24. D.C. Beyer, T. McKeough, and T. Thomas Impact of short course hormonal therapy on overall and cancer-specific survival after permanent prostate brachytherapy Int J Radiat Oncol Biol Phys 61 2005 1299
25. A.M. Dosoretz, M.H. Chen, and S.A. Salenius et al. Mortality in men with localized prostate cancer treated with brachytherapy with or without neoadjuvant hormone therapy Cancer 116 2010 837
26. K.H. Nguyen, E.M. Horwitz, and A.L. Hanlon et al. Does short-term androgen deprivation substitute for radiation dose in the treatment of high-risk prostate cancer? Int J Radiat Oncol Biol Phys 57 2003 377
27. M. Bolla, D. Gonzalez, and P. Warde et al. Improved survival in patients with locally advanced prostate cancer treated with radiotherapy and goserelin N Engl J Med 337 1997 295
28. A.V. D'Amico, M.H. Chen, and A.A. Renshaw et al. Androgen suppression and radiation vs radiation alone for prostate cancer: a randomized trial JAMA 299 2008 289
29. H. Konaka, S. Egawa, and S. Saito et al. Tri-modality therapy with I-125 brachytherapy, external beam radiation therapy, and short- or long-term hormone therapy for high-risk localized prostate cancer (TRIP): study protocol for a phase III, multicenter, randomized, controlled trial BMC Cancer 12 2012 110